TY - JOUR
T1 - New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy
AU - Nelson, W. G.
AU - Simons, J. W.
PY - 1996
Y1 - 1996
N2 - Some men affected with clinically localized prostate carcinoma suffer life-threatening recurrence, despite previous treatment with surgery or radiation therapy, underscoring the need for new, effective, systemic adjuvant treatment approaches. Recent molecular mechanism based prostate cancer drug discovery efforts have identified several candidate targets for systemic prostate cancer adjuvant therapy; however, traditional cancer treatment development algorithms may not be appropriate for many of the new treatment strategies. To best exploit the clinical potential of these molecular treatment strategies, novel translational research strategies are required to support hypothesis-driven clinical research and development.
AB - Some men affected with clinically localized prostate carcinoma suffer life-threatening recurrence, despite previous treatment with surgery or radiation therapy, underscoring the need for new, effective, systemic adjuvant treatment approaches. Recent molecular mechanism based prostate cancer drug discovery efforts have identified several candidate targets for systemic prostate cancer adjuvant therapy; however, traditional cancer treatment development algorithms may not be appropriate for many of the new treatment strategies. To best exploit the clinical potential of these molecular treatment strategies, novel translational research strategies are required to support hypothesis-driven clinical research and development.
UR - http://www.scopus.com/inward/record.url?scp=0030482690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030482690&partnerID=8YFLogxK
U2 - 10.1016/S0094-0143(05)70346-3
DO - 10.1016/S0094-0143(05)70346-3
M3 - Article
C2 - 8948421
AN - SCOPUS:0030482690
SN - 0094-0143
VL - 23
SP - 685
EP - 696
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
IS - 4
ER -